New Clinical Perspectives in the Management of Marginal Zone Lymphoma With Ariela Noy, MD, and Matthew Matasar, MD
Keira Smith
Expert Analysis
i3 Health · New Perspectives in the Management of Marginal Zone Lymphoma Marginal zone lymphoma (MZL) comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs) (Cerhan & Haberman, 2021). According to the World Health Organization classification, there are three subtypes: extranodal MZL, also referred to as mucosa-associated l...
Understanding the Research on Novel Treatments and Nutritional Interventions for Multiple Myeloma With Urvi Shah, MD
Keira Smith
Expert Analysis
During the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Urvi Shah from Memorial Sloan Kettering Cancer Center sat down with Oncology Data Advisor to share her perspectives on the exciting research that was presented in the poster discussion session she chaired on novel therapies for multiple myeloma. In addition, Dr. Shah explains more about her work to impact patients' quality of life and outcomes through nutritional interventions.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 
Please Move: Get Your Oncology Patients Exercising With Karen Basen-Engquist, PhD, MPH
Lyn Brook
Expert Analysis
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Karen Basen-Engquist, PhD, MPH, Director of the Center for Energy Balance in Cancer Prevention and Survivorship at The University of Texas MD Anderson Cancer Center, sat down with Oncology Data Advisor after presenting her education session on behavioral strategies to get your patients with cancer exercising and why it is important.  
Diagnosis and Evidence-Based Management of T-Cell Lymphoma With Aaron Goodman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Diagnosis and Evidence-Based Management of T-Cell Lymphoma T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival ...
Tackling Violence and Stigmatization to Decrease Cancer Disparities for Transgender Patients With Ash Alpert, MD, MFA
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Tackling Violence and Stigmatization to Decrease Disparities for Transgender Patients: Ash Alpert At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Ash Alpert, a postdoctoral fellow in health services research at Brown University, presented two posters regarding the associations between violence and cancer risk factors for transgender and cisgender people. In this follow-up interview with Oncology Data Advisor, Dr. Alpert delves further into the implications of these two studies' results and shares how their ongoing research in this field seeks to improve the care of transgender people in the health care setting.  
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
Keira Smith
Expert Analysis
On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.  
Understanding the Current Landscape of Chemotherapy-Induced Neutropenia With Maura Abbott, NP, MSN, PhD
Lyn Brook
Expert Analysis
Chemotherapy-induced neutropenia (CIN) is a common and potentially life-threatening consequence of chemotherapy, as it may lead to serious infections for patients with cancer. These infections result in hospital stays, increased morbidity and mortality, and considerable financial burden. In this interview, Dr. Maura Abbott explains the importance of managing and educating patients about CIN.  
Epic Experiences Available for Cancer Survivors With Colin Ferro
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Thriving Beyond the Cancer Diagnosis: Colin Ferro At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Colin Ferro, Director of Operations at Epic Experience, spoke with Oncology Data Advisor about the organization's mission to empower adult cancer survivors and thrivers beyond their diagnosis and treatment. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 
Treatment Advances in Waldenstrom Macroglobulinemia With Morie Gertz, MD, MACP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Treatment Advances in Waldenstrom Macroglobulinemia Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal immunoglobulin M (IgM) (LLS, 2021). Often considered a disease oc...
Understanding Antibody-Drug Conjugates and Their Use in the Treatment of Breast Cancer With Ian Krop, MD, PhD
Elizabeth Heller, PhD
Expert Analysis
Oncology Data Advisor™ · Patritumab Deruxtecan for HER3-Expressing Metastatic Breast Cancer: Ian Krop, MD, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Ian Krop, Director of the Yale Cancer Center Clinical Trials Office, sat down with Oncology Data Advisor to discuss his research and the data he presented regarding the HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) for treatment of metastatic breast cancer.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMED.  
Changing the Standard of Care for Pediatric Neuroblastoma With Wendy London, PhD
Elizabeth Heller, PhD
Expert Analysis
Oncology Data Advisor™ · Neuroblastoma Risk Stratification and Research: Wendy London, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Wendy London, Associate Professor of Pediatrics at Harvard Medical School, sat down with Oncology Data Advisor to share her research regarding risk stratification, reduction of therapy, and survival outcomes for pediatric patients with neuroblastoma. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
Guiding Colorectal Cancer Treatment Decisions by Using ctDNA With Jeanne Tie, MD, MBChB, FRACP
Elizabeth Heller, PhD
Expert Analysis
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jeanne Tie spoke with Oncology Data Advisor to share more about her presentation regarding the clinical utility of circulating tumor DNA (ctDNA) analysis to guide treatment decision making for patients with colorectal cancer.  
Bridging Disparities in Breast Cancer Morbidity and Mortality in Women of Color With Jessica Jones, MD
Eden Maack
Expert Analysis
Oncology Data Advisor™ · Breast Cancer Prevention and Disparities: Jessica Jones, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Jessica Jones, Assistant Professor of Oncology at the University of Texas (UT) Health System, sat down with Oncology Data Advisor to discuss her work in cancer detection and cancer prevention in Black women with a higher risk of developing breast cancer and bridging the racial gap in breast cancer morbidity and mortality with early detection and prevention.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
Updates in Mantle Cell Lymphoma With John Leonard, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Updates in Mantle Cell Lymphoma Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin lymphoma that comprises approximately 5% of all lymphomas. Compared with patients who have other aggressive lymphomas, patients with MCL often do not respond as well to treatment (ACS, 2...
Advancing Treatment for Non–Small Cell Lung Cancer: Exploring the Results of Adagrasib With Alexander Spira, MD, PhD, FACP
Lyn Brook
Expert Analysis
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Alexander Spira, MD, PhD, FACP, Director of the Thoracic and Phase I Program at the Virginia Cancer Specialists, the US Oncology Network, met with Oncology Data Advisor to discuss his presentation about adagrasib for KRAS G12–mutated non–small cell lung cancer with active central nervous system (CNS) metastases.  
Exploring Treatment Outcomes for Lobular Breast Cancer With Jason Mouabbi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Lobular Breast Cancer Histology and Research: Jason Mouabbi, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jason Mouabbi of MD Anderson Cancer Center presented a poster focused on survival outcomes of patients with invasive lobular carcinoma treated with endocrine therapy plus a CDK4/6 inhibitor, mammalian target of rapamycin (mTOR) inhibitor, or a PI3K inhibitor, in comparison to those with metastatic hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive ductal carcinoma. Afterwards, he sat down with Oncology Data Advisor to explain the implication of the study's results and the need for additional research in the field of lobular breast cancer to improve patient outcomes.  This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.  
Increasing Medical Student Confidence When Treating LGBTQIA+ Patients With Cherry Au, MD
Lyn Brook
Expert Analysis
Following the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Cherry Au, MD, of Rush University Medical Center, spoke with Oncology Data Advisor to discuss her abstract, Medical Student Clinical Cultural Awareness in Cancer Care of Sexual and Gender Minorities.  
Sharing the Breast Cancer Journey From Diagnosis to Survivorship With Megan-Claire Chase
Keira Smith
Expert Analysis
Oncology Data Advisor™ · A Patient's Perspective on Breast Cancer and Advocacy: Megan - Claire Chase At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Megan-Claire Chase, breast cancer survivor and Breast Cancer Program Director at SHARE Cancer Support, sat down with Oncology Data Advisor to talk about her diagnosis, treatment, and survivorship journey, as well as her advocacy work to empower people living with cancer. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 
Updates in Myelodysplastic Syndromes: Improving Patient Outcomes With Mikkael Sekeres, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Updates in Myelodysplastic Syndromes: Improving Patient Outcomes Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid malignancies that derive from abnormal multipotent progenitor cells and are characterized by bone marrow failure and peripheral blood cytopenias (NCCN, 2021; Garci...
Understanding the Research on Novel Treatments and Nutritional Interventions for Multiple Myeloma With Urvi Shah, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Best of Multiple Myeloma Research at ASCO: Urvi Shah, MD During the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Urvi Shah from Memorial Sloan Kettering Cancer Center sat down with Oncology Data Advisor to share her perspectives on the exciting research that was presented in the poster discussion session she chaired on novel therapies for multiple myeloma. In addition, Dr. Shah explains more about her work to impact patients' quality of life and outcomes through nutritional interventions. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 

Copyright © 2022 Oncology Data Advisor. All rights reserved.